Explore the BIO Digital 2021 Sessions below.
The art of deal-making is multi-faceted, and most know the basic requirements of a good deal…
One Health, or the concept that animal, human, and environmental health are interconnected, has…
In 2020, vaccine developers moved swiftly to find COVID-19 vaccine candidates, using pioneering…
The COVID-19 pandemic has highlighted the critical public health role for rapid, accurate and…
Machine learning has the potential to help scientists transform several elements of disease…
Catch our morning re-cap - and what to look out for this afternoon - with BIO Digital Emcee,…
We have been starkly reminded that infectious disease pandemics are very costly to society - but…
The COVID-19 pandemic has shown us that it is possible to speed up clinical trials. …
Infectious diseases like to travel and they often do so incognito with no passports required,…
In the current environment, nascent biotech companies can raise funding from a variety of…
Data and evidence are important – but in the era of alternative facts, they may not matter…
With a 175% increase in announced SPAC M&As for biopharma deals between 2019 and 2020, it…
The onset of COVID-19 required rapid development and availability of potential treatments. …
Vaccines have gone from under the radar to everywhere in the mind of the public and many new…
IPOs and after-market performance have continued at a breakneck pace. The influx of investor…
How we conduct clinical trials has been evolving as a result of new technologies and tools …
Dealmakers adjusted to the new landscape of remote work and navigating a global health crisis in…
Catch our morning re-cap - and what to look out for this afternoon - with BIO Digital Emcee,…
Biomedical data are being generated and digitized at a historic rate. But making use of these…
As challenges in the U.S.-China bilateral relationship continue to affect the business…
The pandemic forced support ecosystems for emerging biotechs to adapt their processes to…
This interactive and practical program will focus on the ongoing impact of the pandemic on…
Commercialization was once considered the last mile for any digital medicine company or…
The IPO Class has grown over the last 8 years and continued through a COVID-19 inflection. This…
The COVID-19 pandemic has highlighted health inequities not only within the United States, but…
Innovative collaborations increasingly play a vital role in ensuring that the latest scientific…
Gene therapies are transforming patients’ lives in ways unimaginable 20 years ago&mdash…
With the onset of the COVID-19 pandemic, violence and harassment of members of the AAPI…
Collaboration among industry stakeholders is essential to discovering and developing emerging I…
What we eat and how we access food is transforming and investment trends in food and ag tech…
Catch our morning re-cap - and what to look out for this afternoon - with BIO Digital Emcee,…
The COVID-19 pandemic has underscored the critical role of science in our ability to live…
Now more than ever, science is entering the public consciousness – from Covid-19 to…
People living with a rare disease or condition not only face unique medical challenges in living…
As Japan pursues its bioeconomy strategy, there are a variety of key policy considerations that…
Effective targeting and activation of innate and adaptive immune cells represents a highly…
Patients are more involved in their healthcare decision-making today than ever before, and are…
For over a decade now, the patient’s journey through the healthcare system has been…
This event brings together thought leaders from the across the biotechnology ecosystem to share…
BIO, in partnership with Coqual, is launching the second-annual Measuring Diversity and…
After a year of pandemic-related innovation priorities, economic and workplace upheaval, and…
Catch Brooke Baldwin's final mid-day highlights reel as BIO Digital's emcee! See what' on the…
In an age of crisis, can the biopharma industry withstand global shocks?
2020 revealed…
Companies, investors, and shareholders have business imperatives to ensure boards reflect the…
Current federal and state reimbursement systems are not nimble enough to accommodate the pace of…
Advances in biotechnology innovation have had a vital impact on the U.S. economy — life…
One of the pillars of the BIOEquality Agenda is expanding opportunities in the industry for…
Safety concerns about COVID-19 have led many patients to delay routine healthcare screenings,…
Times are changing, and we all need to evolve to enable a faster pace to…
With digital transformations all around us in healthcare, business, and our day-to-day lives,…
Promoting health equity and eliminating systemic inequalities in the biotech ecosystem are…
Thank you for being a part of the BIO Digital partnerships, connections, and conversations that…
